Detalhe da pesquisa
1.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
N Engl J Med
; 390(10): 875-888, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38446675
2.
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
N Engl J Med
; 389(19): 1778-1789, 2023 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870949
3.
Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.
Br J Cancer
; 130(3): 369-379, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38102228
4.
TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature
; 554(7693): 544-548, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29443960
5.
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
BJU Int
; 132(2): 170-180, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748180
6.
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
Curr Opin Urol
; 33(5): 404-411, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37265341
7.
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Int J Cancer
; 151(11): 2004-2011, 2022 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603905
8.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029306
9.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 872-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991512
10.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721560
11.
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
J Urol
; 206(2): 240-251, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33835866
12.
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Future Oncol
; 17(2): 137-149, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32938232
13.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1574-1588, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32971005
14.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753727
15.
Management of the penile squamous cell carcinoma patient after node positive radical inguinal lymph node dissection: current evidence and future prospects.
Curr Opin Urol
; 30(2): 223-228, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31895078
16.
Accelerating neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Lancet Oncol
; 25(2): 156-157, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142700
17.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 391(10122): 748-757, 2018 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29268948
18.
Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.
J Urol
; 201(3): 478-485, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30321552
19.
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Int J Cancer
; 143(7): 1764-1773, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29672836
20.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet
; 389(10064): 67-76, 2017 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27939400